506 related articles for article (PubMed ID: 22218276)
1. Long-lasting treatment effect of rituximab in MuSK myasthenia.
Díaz-Manera J; Martínez-Hernández E; Querol L; Klooster R; Rojas-García R; Suárez-Calvet X; Muñoz-Blanco JL; Mazia C; Straasheijm KR; Gallardo E; Juárez C; Verschuuren JJ; Illa I
Neurology; 2012 Jan; 78(3):189-93. PubMed ID: 22218276
[TBL] [Abstract][Full Text] [Related]
2. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients.
Illa I; Diaz-Manera J; Rojas-Garcia R; Pradas J; Rey A; Blesa R; Juarez C; Gallardo E
J Neuroimmunol; 2008 Sep; 201-202():90-4. PubMed ID: 18653247
[TBL] [Abstract][Full Text] [Related]
3. Rituximab in the treatment of MuSK antibody-positive myasthenia gravis.
Stein B; Bird SJ
J Clin Neuromuscul Dis; 2011 Mar; 12(3):163-4. PubMed ID: 21321497
[No Abstract] [Full Text] [Related]
4. Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis.
Marino M; Basile U; Spagni G; Napodano C; Iorio R; Gulli F; Todi L; Provenzano C; Bartoccioni E; Evoli A
Front Immunol; 2020; 11():613. PubMed ID: 32431692
[TBL] [Abstract][Full Text] [Related]
5. Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review.
Hehir MK; Hobson-Webb LD; Benatar M; Barnett C; Silvestri NJ; Howard JF; Howard D; Visser A; Crum BA; Nowak R; Beekman R; Kumar A; Ruzhansky K; Chen IA; Pulley MT; LaBoy SM; Fellman MA; Greene SM; Pasnoor M; Burns TM
Neurology; 2017 Sep; 89(10):1069-1077. PubMed ID: 28801338
[TBL] [Abstract][Full Text] [Related]
6. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
Maddison P; McConville J; Farrugia ME; Davies N; Rose M; Norwood F; Jungbluth H; Robb S; Hilton-Jones D
J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):671-3. PubMed ID: 20392977
[TBL] [Abstract][Full Text] [Related]
7. Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis.
Kuntzer T; Carota A; Novy J; Cavassini M; Du Pasquier RA
Neurology; 2011 Feb; 76(8):757-8. PubMed ID: 21339503
[No Abstract] [Full Text] [Related]
8. Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients.
Keung B; Robeson KR; DiCapua DB; Rosen JB; O'Connor KC; Goldstein JM; Nowak RJ
J Neurol Neurosurg Psychiatry; 2013 Dec; 84(12):1407-9. PubMed ID: 23761915
[No Abstract] [Full Text] [Related]
9. High efficacy of rituximab for myasthenia gravis: a comprehensive nationwide study in Austria.
Topakian R; Zimprich F; Iglseder S; Embacher N; Guger M; Stieglbauer K; Langenscheidt D; Rath J; Quasthoff S; Simschitz P; Wanschitz J; Windisch D; Müller P; Oel D; Schustereder G; Einsiedler S; Eggers C; Löscher W
J Neurol; 2019 Mar; 266(3):699-706. PubMed ID: 30649616
[TBL] [Abstract][Full Text] [Related]
10. Longstanding and Refractory Anti-Muscle Specific Tyrosine Kinase Antibody-Associated Myasthenia Gravis (Anti-MuSK-MG) in a Child Successfully Treated with Rituximab.
Weger S; Appendino JP; Clark IH
J Binocul Vis Ocul Motil; 2019; 69(1):26-29. PubMed ID: 30811277
[TBL] [Abstract][Full Text] [Related]
11. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
Evoli A; Tonali PA; Padua L; Monaco ML; Scuderi F; Batocchi AP; Marino M; Bartoccioni E
Brain; 2003 Oct; 126(Pt 10):2304-11. PubMed ID: 12821509
[TBL] [Abstract][Full Text] [Related]
12. MuSK-Ab positive myasthenia: not always grave.
Zouvelou V; Stamboulis E; Skriapa L; Tzartos SJ
J Neurol Sci; 2013 Aug; 331(1-2):150-1. PubMed ID: 23706725
[TBL] [Abstract][Full Text] [Related]
13. Short-term effect of low-dose rituximab on myasthenia gravis with muscle-specific tyrosine kinase antibody.
Zhou Y; Yan C; Gu X; Zhou L; Lu J; Zhu W; Huan X; Luo S; Zhong H; Lin J; Lu J; Zhao C; Xi J
Muscle Nerve; 2021 Jun; 63(6):824-830. PubMed ID: 33745138
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in refractory MuSK antibody myasthenia gravis.
Thakre M; Inshasi J; Marashi M
J Neurol; 2007 Jul; 254(7):968-9. PubMed ID: 17468964
[No Abstract] [Full Text] [Related]
15. Rituximab in the management of refractory myasthenia gravis.
Zebardast N; Patwa HS; Novella SP; Goldstein JM
Muscle Nerve; 2010 Mar; 41(3):375-8. PubMed ID: 19852027
[TBL] [Abstract][Full Text] [Related]
16. Anti-MuSK myasthenia gravis presenting with purely ocular findings.
Caress JB; Hunt CH; Batish SD
Arch Neurol; 2005 Jun; 62(6):1002-3. PubMed ID: 15956173
[TBL] [Abstract][Full Text] [Related]
17. Long-term effect of intravenous immunoglobulin on anti-MuSK antibody-positive myasthenia gravis.
Shibata-Hamaguchi A; Samuraki M; Furui E; Iwasa K; Yoshikawa H; Hayashi S; Yamada M
Acta Neurol Scand; 2007 Dec; 116(6):406-8. PubMed ID: 17986100
[TBL] [Abstract][Full Text] [Related]
18. Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis.
Deymeer F; Gungor-Tuncer O; Yilmaz V; Parman Y; Serdaroglu P; Ozdemir C; Vincent A; Saruhan-Direskeneli G
Neurology; 2007 Feb; 68(8):609-11. PubMed ID: 17310034
[TBL] [Abstract][Full Text] [Related]
19. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.
Farrugia ME; Robson MD; Clover L; Anslow P; Newsom-Davis J; Kennett R; Hilton-Jones D; Matthews PM; Vincent A
Brain; 2006 Jun; 129(Pt 6):1481-92. PubMed ID: 16672291
[TBL] [Abstract][Full Text] [Related]
20. Selective response to rituximab in a young child with MuSK-associated myasthenia gravis.
Govindarajan R; Iyadurai SJ; Connolly A; Zaidman C
Neuromuscul Disord; 2015 Aug; 25(8):651-2. PubMed ID: 25998611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
